KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Non-Current Debt (2016 - 2025)

BeOne Medicines (ONC) has disclosed Non-Current Debt for 11 consecutive years, with $139.6 million as the latest value for Q3 2025.

  • On a quarterly basis, Non-Current Debt changed N/A to $139.6 million in Q3 2025 year-over-year; TTM through Sep 2025 was $139.6 million, a N/A change, with the full-year FY2024 number at $166.5 million, down 15.75% from a year prior.
  • Non-Current Debt was $139.6 million for Q3 2025 at BeOne Medicines, down from $146.1 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $209.1 million in Q4 2022 to a low of $139.6 million in Q3 2025.
  • A 5-year average of $184.2 million and a median of $193.0 million in 2021 define the central range for Non-Current Debt.
  • Peak YoY movement for Non-Current Debt: surged 135.64% in 2021, then decreased 21.15% in 2025.
  • BeOne Medicines' Non-Current Debt stood at $202.1 million in 2021, then rose by 3.48% to $209.1 million in 2022, then fell by 5.51% to $197.6 million in 2023, then decreased by 15.75% to $166.5 million in 2024, then dropped by 16.17% to $139.6 million in 2025.
  • Per Business Quant, the three most recent readings for ONC's Non-Current Debt are $139.6 million (Q3 2025), $146.1 million (Q2 2025), and $160.2 million (Q1 2025).